{
    "organizations": [],
    "uuid": "2238e5ec45935f5a308f9ca0c7ee86b6e7b82cd7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novartis-generics-head-sees-us-pri/brief-novartis-generics-head-sees-u-s-price-pressure-in-2018-idUSZ8N15A01N",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis generics head sees U.S. price pressure in 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 24 (Reuters) - Novartis:\n* SANDOZ HEAD SAYS U.S. PRICING PRESSURE TO CONTINUE IN 2018, WILL ABATE AS BIOSIMILARS COME THROUGH IN COMING YEARS\n* CEO SAYS CONTINUES TO EXPECT BIOSIMILARS TO BE A MULTI-BILLION DOLLAR BUSINESS, BUT MUST OVERCOME PATENT HURDLES IN UNITED STATES Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)\n ",
    "published": "2018-01-24T22:38:00.000+02:00",
    "crawled": "2018-01-25T13:10:51.051+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "novartis",
        "sandoz",
        "head",
        "say",
        "pricing",
        "pressure",
        "continue",
        "abate",
        "biosimilars",
        "come",
        "coming",
        "year",
        "ceo",
        "say",
        "continues",
        "expect",
        "biosimilars",
        "dollar",
        "business",
        "must",
        "overcome",
        "patent",
        "hurdle",
        "united",
        "state",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "zurich",
        "newsroom"
    ]
}